ATOPICA 50 mg

Main information

  • Trade name:
  • ATOPICA 50 mg
  • Pharmaceutical form:
  • Capsule, soft
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ATOPICA 50 mg
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ciclosporin
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0137/003
  • Authorization date:
  • 26-07-2007
  • EU code:
  • FR/V/0137/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

ATOPICA50mgSPC. [updateofADRsection,January2013]

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

ATOPICA50mgsoftcapsulesfordogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Ciclosporin 50.00mg

Excipient(s):

-tocopherol(E-307) 0.50mg

Titaniumdioxide(E-171)4.50mg

Carminicacid(E-120)<1.00

g

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Softcapsule

Yellow-whiteoblongcapsulesbearingthefollowingimprint:NVR50mg.

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs(weighingfrom7.5to36kg)

4.2Indicationsforuse,specifyingthetargetspecies

Treatmentofchronicmanifestationsofatopicdermatitisindogs.

4.3Contraindications

Donotuseincasesofhypersensitivitytociclosporinoroneoftheexcipients.

Forallcapsulestrengths,donotuseindogslessthansixmonthsofageorlessthan2kgin

weight.

Donotuseincaseswithahistoryofmalignantdisordersorprogressivemalignantdisorders.

Donotvaccinatewithalivevaccineduringtreatmentorwithinatwo-weekintervalbeforeor

aftertreatment.(seealsosections4.5“Specialprecautionsforuse”and4.8“Interactionwith

othermedicinalproducts”).

4.4Specialwarnings

None.

4.5Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

Clinicalsignsofatopicdermatitissuchaspruritusandskininflammationarenotspecificfor

thisdiseaseandthereforeothercausesofdermatitissuchasectoparasiticinfestations,other

allergieswhichcausedermatologicalsigns(e.g.fleaallergicdermatitisorfoodallergy)or

bacterialandfungalinfectionsshouldberuledoutbeforetreatmentisstarted.Itisgood

practicetotreatfleainfestationsbeforeandduringtreatmentofatopicdermatitis.

Itisrecommendedtoclearbacterialandfungalinfectionsbeforeadministeringtheveterinary

medicinalproduct.However,infectionsoccurringduringtreatmentarenotnecessarilya

reasonfordrugwithdrawal,unlesstheinfectionissevere.

Acompleteclinicalexaminationshouldbeperformedbeforetreatment.Asciclosporininhibits

T-lymphocytesandthoughitdoesnotinducetumors,itmayleadtoincreasedincidencesof

clinicallyapparentmalignancy.Lymphadenopathyobservedontreatmentwithciclosporin

shouldberegularlymonitored.

Inlaboratoryanimals,ciclosporinisliabletoaffectthecirculatinglevelsofinsulinandtocause

anincreaseinglycaemia.Inthepresenceofsuggestivesignsofdiabetesmellitus,theeffect

oftreatmentonglycaemiamustbemonitored.Ifsignsofdiabetesmellitusareobserved

followingtheuseoftheproduct,e.g.polyuriaorpolydipsia,thedoseshouldbetaperedor

discontinuedandveterinarycaresought.Theuseofciclosporinisnotrecommendedin

diabeticdogs.

Closelymonitorcreatininelevelsindogswithsevererenalinsufficiency.

Particularattentionmustbepaidtovaccination.Treatmentwiththeveterinarymedicinal

productmayinterferewithvaccinationefficacy.Inthecaseofinactivatedvaccines,itisnot

recommendedtovaccinateduringtreatmentorwithinatwo-weekintervalbeforeorafter

administrationoftheproduct .Forlivevaccinesseealsosection4.3“Contraindications”.

Itisnotrecommendedtouseotherimmunosuppressiveagentsconcomitantly.

ii)Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsafteradministration.

Inthecaseofaccidentalingestionofthecapsuleoritscontents,seekmedicaladvice

immediatelyandshowthepackageleafletorthelabeltothephysician.

4.6Adversereactions(frequencyandseriousness)

Theoccurrenceofadversereactionsisuncommon. Themostfrequentlyobserved

undesirableeffectsaregastrointestinaldisturbancessuchasvomiting,mucoidorsoftfaeces

anddiarrhoea.Theyaremildandtransientandgenerallydonotrequirethecessationofthe

treatment.

Otherundesirableeffectsmaybeobservedinfrequently:lethargyorhyperactivity,anorexia,

mildtomoderategingivalhyperplasia,skinlesionssuchasverruciformlesionsorchangeof

haircoat,redandswollenpinnae,muscleweaknessormusclecramps.Theseeffects

generallyresolvespontaneouslyaftertreatmentisstopped.

Veryrarelydiabetesmellitushasbeenobserved,reportedmainlyinWestHighlandWhite

Terriers.

Asforthesu bjectofmalignancy,pleaseseesections4.3“Contraindications”and4.5“Special

precautionsforuse”.

4.7Useduringpregnancy,lactationorlay

Inlaboratoryanimals,atdoseswhichinducematernaltoxicity(ratsat30mg/kgbwand

rabbitsat100mg/kgbw)ciclosporinwasembryo-andfetotoxic,asindicatedbyincreased

pre-andpostnatalmortalityandreducedfoetalweighttogetherwithskeletalretardations.In

thewell-tolerateddoserange(ratsatupto17mg/kgbwandrabbitsatupto30mg/kgbw)

ciclosporinwaswithoutembryolethalorteratogeniceffects.Thesafetyofthedrughasneither

beenstudiedinbreedingmaledogsnorinpregnantorlactatingfemaledogs.Intheabsence

ofsuchstudiesinthedog,itisrecommendedtousethedruginbreedingdogsonlyupona

positiverisk/benefitassessmentbytheveterinarian.Ciclosporinpassestheplacentabarrier

andisexcretedviamilk.Thereforethetreatmentoflactatingbitchesisnotrecommended.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Varioussubstancesareknowntocompetitivelyinhibitorinducetheenzymesinvolvedinthe

metabolismofciclosporin,inparticularcytochromeP450(CYP3A4).Incertainclinically

justifiedcases,anadjustmentofthedosageoftheveterinarymedicinalproductmaybe

required.Ketoconazoleat5-10mg/kgisknowntoincreasethebloodconcentrationof

ciclosporinindogsuptofive-fold,whichisconsideredtobeclinicallyrelevant.During

concomitantuseofketoconazoleandciclosporintheveterinarianshouldconsiderasa

practicalmeasuretodoublethetreatmentintervalifthedogisonadailytreatmentregime.

Macrolidessuchaserythromycinmayincreasetheplasmalevelsofciclosporinuptotwofold.

Certain inducers of cytochrome P450, anticonvulsants and antibiotics (e.g.

trimethoprim/sulfadimidine)maylowertheplasmaconcentrationofciclosporin.

CiclosporinisasubstrateandaninhibitoroftheMDR1P-glycoproteintransporter.Therefore,

theco-administrationofciclosporinwithP-glycoproteinsubstratessuchasmacrocyclic

lactones(e.g.ivermectinandmilbemycin)coulddecreasetheeffluxofsuchdrugsfrom

blood-brainbarriercells,potentiallyresultinginsignsofCNStoxicity.

Ciclosporincanincreasethenephrotoxicityofaminoglycosideantibioticsandtrimethoprim.

Theconcomitantuseofciclosporinisnotrecommendedwiththeseactiveingredients.

Particularattentionmustbepaidtovaccination(seesections4.3“Contraindications”and4.5

“Specialprecautionsforuse”).

4.9Amountstobeadministeredandadministrationroute

Themeanrecommendeddoseofciclosporinis5mg/kgbodyweightaccordingtothe

followingscheme.

–Foradogweighing7.5to<15kgonecapsuleoftheveterinarymedicinalproduct

–Foradogweighing15to<29kgtwocapsulesoftheveterinarymedicinalproduct

–Foradogweighing29to<36kgthreecapsulesoftheveterinarymedicinalproduct

Theveterinarymedicinalproductwillinitiallybegivendailyuntilasatisfactoryclinical

improvementisseen.Thiswillgenerallybethecasewithin4weeks.Ifnoresponseis

obtainedwithinthefirst8weeks,thetreatmentshouldbestopped.

Oncetheclinicalsignsofatopicdermatitisaresatisfactorilycontrolled,thepreparationcan

thenbegiveneveryotherdayasamaintenancedose.Theveterinarianshouldperforma

clinicalassessmentatregularintervalsandadjustthefrequencyofadministrationtothe

clinicalresponseobtained.

Insomecaseswheretheclinicalsignsarecontrolledwithevery-other-daydosing,the

veterinariancandecidetogivetheveterinarymedicinalproductevery3to4days.

Adjuncttreatment(e.g.medicatedshampoos,fattyacids)maybeconsideredbeforereducing

thedosinginterval.

Treatmentmaybestoppedwhentheclinicalsignsarecontrolled.Uponrecurrenceofclinical

signs,treatmentshouldberesumedatdailydosing,andincertaincasesrepeatedtreatment

coursesmayberequired.

Theveterinarymedicinalproductshouldbegivenatleast2hoursbeforeorafterfeeding.

Insertthecapsuledirectlyintothedog’smouth.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noundesirableeffectsbeyondthosethatwereseenunderrecommendedtreatmenthave

beenobservedinthedogwithasingleoraldoseofupto6timesofwhatisrecommended.

Inadditiontowhatwasseenunderrecommendeddosage,thefollowingadversereactions

wereseenincaseofoverdosefor3monthsormoreat4timesthemeanrecommended

dosage:hyperkeratoticareasespeciallyonthepinnae,callous-likelesionsofthefootpads,

weightlossorreducedweightgain,hypertrichosis,increasederythrocytesedimentationrate,

decreasedeosinophilvalues.Frequencyandseverityofthesesignsaredosedependent.

Thereisnospecificantidoteandincaseofsignsofoverdosethedogshouldbetreated

symptomatically.Thesignsarereversiblewithin2monthsfollowingcessationoftreatment.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Selectiveimmunosuppressiveagents.

ATCvetcodeQL04AD01.

5.1Pharmacodynamicproperties

Ciclosporin(alsoknownascyclosporin,cyclosporine,cyclosporineA,CsA)isaselective

immunosuppressor.Itisacyclicpolypeptideconsistingof11aminoacids,hasamolecular

weightof1203daltonsandactsspecificallyandreversiblyonTlymphocytes.

Ciclosporinexertsanti-inflammatoryandantipruriticeffectsinthetreatmentofatopic

dermatitis.CiclosporinhasbeenshowntopreferentiallyinhibittheactivationofT-lymphocytes

onantigenicstimulationbyimpairingtheproductionofIL-2andotherT-cellderivedcytokines.

Ciclosporinalsohasthecapacitytoinhibittheantigen-presentingfunctionontheskinimmune

system.Itlikewiseblockstherecruitmentandactivationofeosinophils,theproductionof

cytokinesbykeratinocytes,thefunctionsofLangerhanscells,thedegranulationofmastcells

andthereforethereleaseofhistamineandpro-inflammatorycytokines.

Ciclosporindoesnotdepresshaematopoiesisandhasnoeffectonthefunctionofphagocytic

cells.

5.2Pharmacokineticparticulars

Absorption

Thebioavailabilityofciclosporinisabout35%.Thepeakplasmaconcentrationisreached

within1to2hours.Thebioavailabilityisbetterandlesssubjecttoindividualvariationsif

ciclosporinisadministeredtofastedanimalsratherthanatmealtimes.

Distribution

Indogs,thevolumeofdistributionisabout7.8L/kg.Ciclosporiniswidelydistributedtoall

tissues.Followingrepeateddailyadministrationtodogsciclosporinconcentrationintheskin

isseveraltimeshigherthaninblood.

Metabolism

CiclosporinismetabolisedmainlyintheliverbycytochromeP450(CYP3A4),butalsointhe

intestine.Metabolismtakesplaceessentiallyintheformofhydroxylationanddemethylation,

leadingtometaboliteswithlittleornoactivity.Unchangedciclosporinrepresentsabout25%of

circulatingbloodconcentrationsinthecourseofthefirst24hours.

Elimination

Eliminationismainlyviathefaeces.Only10%isexcretedintheurine,mostlyintheformof

metabolites.Nosignificantaccumulationwasobservedinbloodofdogstreatedforoneyear.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Carminicacid(E-120)

Cornoil-mono-di-triglycerides

Ethanol(E-1510)

Gelatine(E-441)

Glycerol(E-422)

Macrogolglycerolhydroxystearate

Propyleneglycol(E-1520)

Titaniumdioxide(E-171)

-Tocopherol(E-307)

6.2Incompatibilities

Notapplicable.

6.3Shelflife

3years

6.4.Specialprecautionsforstorage

Donotstoreabove25

C.Keepthemedicinalproductintheblisterpack.Keeptheblister

packintheoutercarton.

6.5Natureandcompositionofimmediatepackaging

Boxcontaining15capsulesin3aluminium/aluminiumblisterpacks

Boxcontaining30capsulesin6aluminium/aluminiumblisterpacks

Boxcontaining60capsulesin12aluminium/aluminiumblisterpacks

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialderivedfromsuchveterinary

shouldbedisposedofinaccordancewithnationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

NovartisSanteAnimaleS.A.S.

14,bdRichelieu

F-92500Rueil-Malmaison

France

8. MARKETINGAUTHORISATIONNUMBER(S)

Boxcontaining3blisterpacks:---

Boxcontaining6blisterpacks:---

Boxcontaining12blisterpacks:---

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

12.08.2002/July2007

10.DATEOFREVISIONOFTHETEXT

May2008

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

29-11-2018

ANSES Newsletter in English - N°50 - November 2018

ANSES Newsletter in English - N°50 - November 2018

France - Agence Nationale du Médicament Vétérinaire

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

25-7-2018

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

Associated Milk Producers Inc. (AMPI) of New Ulm, Minn., is recalling dry whey powder packaged in 50-pound and 25-kg bags that were produced at the cooperative’s Blair, Wis., dry whey plant from May 1-5, 2018; May 24-29, 2018; June 2-5, 2018; and June 7-14, 2018 due to the potential to be contaminated with Salmonella. This is a precautionary recall. All products shipped to the marketplace tested negative for Salmonella.

FDA - U.S. Food and Drug Administration

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

19-9-2018

Targretin (Eisai GmbH)

Targretin (Eisai GmbH)

Targretin (Active substance: bexarotene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6098 of Wed, 19 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/326/T/50

Europe -DG Health and Food Safety

10-7-2018

Verkazia (Santen Oy)

Verkazia (Santen Oy)

Verkazia (Active substance: ciclosporin) - Centralised - Authorisation - Commission Decision (2018)4469 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4411

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety

1-6-2018

Withdrawn application:  Restaysis, ciclosporin, Initial authorisation

Withdrawn application: Restaysis, ciclosporin, Initial authorisation

Europe - EMA - European Medicines Agency